https://doi.org/10.55788/423cdf5c
How important are high levels of skin clearance for patients with psoriasis and their quality-of-life? To answer this question, Prof. Matthias Augustin (University Medical Centre Hamburg, Germany) and his group performed a retrospective cohort study based on data from the PsoBest registry [1]. The study analysed PASI, DLQI, and Patient Benefit Index (PBI) 1 year after starting systemic treatment for psoriasis. Over 3,800 adults with moderate-to-severe disease who continued until visit 4 at 12 months were evaluated. As for previous treatments, 45.2% never had systemic therapy, and 14.9% already had been on biologics, the latter representing 41.3% of systemic treatments.
The clinical outcomes revealed that about one-third of patients presented with PASI 100 or 90/100 after 1 year. This coincided with a DLQI of 0/1, which stands for “no impact on quality-of-life” in 47.2% of cases. However, around 10% of patients still had a DLQI >10.
Assessing therapy achievements from the patients’ point of view, PBI values of ≥3.5 were observed in 24.2% of cases, indicating the highest treatment benefit. Again, a high level of skin clearance showed a positive effect on this outcome: PASI100 and 90/100 were associated with 49% and 36.1% of PBI ≥3.5, respectively, while this score was only achieved by 10.4% of those with PASI <75 (see Figure).
Figure: Skin clearance improvements in relation to Patient Benefit Index (PBI) [1]
Several baseline factors have an impact on the likelihood of an unimpaired quality-of-life (DLQI 0/1). The odds were increased by treatment with biologics (P<0.001), higher age (P=0.002), and longer-standing disease (P=0.004). The chances of DLQI 0/1 were lower in the case of >2 comorbidities (P=0.004), female sex (P=0.001), and raised BMI (P=0.002).
In his summary, Prof. Augustin highlighted 3 aspects of the results: only a minority of psoriasis patients achieved complete skin clearance after 12 months of systemic treatment; those with better skin clearance reached a DLQI 0/1 or a PBI ≥3.5 at higher proportions; and a completely cleared skin is of key importance for the patients.
- Augustin M, et al. Value of skin clearance on patient-reported quality of life and treatment benefit, in patients with moderate to severe psoriasis in Germany. BOS10, SPIN 2022 Congress, 06–08 July, Paris, France.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Predilection sites for skin signs of vitiligo disease activity determined Next Article
Paediatric psoriasis: ixekizumab beneficial in difficult-to-treat areas »
« Predilection sites for skin signs of vitiligo disease activity determined Next Article
Paediatric psoriasis: ixekizumab beneficial in difficult-to-treat areas »
Table of Contents: SPIN 2022
Featured articles
Letter from the Editor
IMIDs in Adults and Children: New Developments
Therapies for atopic dermatitis: still moving forward
Children with AD: high risk of bacterial infections in carriers of a filaggrin gene variant
Men on biologics report fewer adverse events than women
Conceptual framework of adverse drug reactions may improve treatment of patients with IMIDs
Psoriasis: The Beat Goes On
Systemic treatment for psoriasis: what is on the horizon?
Topical therapy in psoriasis: an important partner in combination therapy
GPP flares: pronounced undertreatment is common
IL-17A/F inhibitor bimekizumab shows higher response and maintenance rates compared with secukinumab
Paediatric psoriasis: ixekizumab beneficial in difficult-to-treat areas
Psoriasis patients see great benefit in achieving complete skin clearance
The Future Is Bright for Vitiligo
Predilection sites for skin signs of vitiligo disease activity determined
Where Are We Now in Hidradenitis Suppurativa
IHS4 better suited as an outcome measure in HS trials?
New treatments for HS: IL-17 inhibitors next in practice?
New Treatment Options in Alopecia Areata
Alopecia areata: light at the end of the tunnel
Alopecia areata pathogenesis: known genetic background, unknown environmental triggers
Best of the Posters
Psoriasis treatment: no elevation of MACE and VTE on deucravacitinib
Comorbid anxiety and depression may benefit from psoriasis treatment with certolizumab
Dose tapering in psoriasis is associated with a low relapse rate
Related Articles
November 28, 2023
High-dose subcutaneous spesolimab prevents GPP flares up to week 48
October 9, 2019
Certolizumab pegol efficacious for head and neck psoriasis
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com